Iovance Biotherapeutics completes patient dosing in cohort 4 of C-144-01 study
Iovance Biotherapeutics announced that the company has completed dosing the last patient in the registration-enabling Cohort 4 of the C-144-01 study of lifileucel in the treatment of patients with advanced melanoma. Cohort 4 has the primary endpoint of objective response rate to be read out by an Independent Review Committee.Iovance Tumor Infiltrating Lymphocytes for melanoma, lifileucel, is an investigational, patient-derived cell therapy that involves a 22-day manufacturing process at a centralized facility. Cohort 4 in the C-144-01 study includes post-PD-1 patients with Stage IIIC/IV unresectable melanoma who also have received BRAF/MEK therapy if clinically indicated. Lifileucel has been granted Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug designations in advanced melanoma.